Hormonal contraception in patients with epilepsy by Bosak, Magdalena et al.
61
ORIGINAL PAPER /  GYNECOLOGY
Ginekologia Polska
2019, vol. 90, no. 2, 61–65
Copyright © 2019 Via Medica
ISSN 0017–0011
DOI: 10.5603/GP.2019.0010
Corresponding author:
Magdalena Bosak
Collegium Medicum, Jagiellonian University of Cracow, Poland
e-mail: magdalena.bosak@uj.edu.pl
Hormonal contraception in patients with epilepsy
Magdalena Bosak, Katarzyna Cyranka, Agnieszka Slowik
Collegium Medicum, Jagiellonian University of Cracow, Poland
ABSTRACT
Objectives: The aim of the study was to evaluate hormonal contraception use in women with epilepsy and to assess the 
risk of potential interactions between contraceptives and antiepileptic drugs (AEDs).
Material and methods: Data on hormonal contraception were obtained prospectively in women of childbearing age 
treated in the university epilepsy clinic.
Results: We evaluated 334 women with epilepsy (mean age 30.2 years). The majority of patients took one AED (193, 58%); 
the most commonly prescribed AEDs were: valproate, levetiracetam or lamotrigine. Hormonal contraception was used by 
19 (5.7%) of all women of childbearing age. Only 7 patients (37%) of all those using hormonal contraception used prepa-
rations that did not interact with AEDs; what is more 145 (46%) patients who did not use hormonal contraception were 
prescribed AEDs with high teratogenic potential (valproate or/and topiramate).
Conclusions: A very small percentage of women with epilepsy of childbearing potential used hormonal contraception. More 
than a half of that group simultaneously took AEDs that may interact with oral contraceptives. A large proportion of women 
taking AEDs with high teratogenic potential were not using hormonal contraception. As interaction between OC and AEDs 
are common, nonhormonal, highly effective methods, such as IUDs, may be ideal for women with epilepsy. The results of 
the study indicate the need for closer cooperation between neurologist and gynecologist caring for women with epilepsy.
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INTRODUCTION
With an estimated point prevalence of 6.4 per 
1,000 persons, epilepsy is one of the most frequent chron-
ic neurological disorders [1]. Both epileptic seizures and 
their pharmacotherapy may negatively affect reproductive 
health-related issues, especially in women with epilepsy 
(WWE). Antiepileptic drugs (AEDs) must be used in WWE 
for many years, and sometimes throughout life, also during 
reproductive age. One of the most important side effects 
of pharmacotherapy of WWE is the teratogenic potential 
of AEDs. The results of prospective observational registers 
of pregnancies in WWE indicate an increased risk of birth 
defects in children exposed to AEDs in utero. The latest re-
port of the largest pregnancy and epilepsy register EURAP 
International showed 4.9% risk of major congenital mal-
formation in offspring of women taking AEDs during preg-
nancy [2]. Another aspect of the treatment of epilepsy in 
women are the bidirectional pharmacokinetic interactions 
between oral contraceptives (OC) and AEDs , which may 
lead to a reduction in the effectiveness of contraception 
and/or AEDs [3]. Ethinylestradiol (EE) metabolism may be 
accelerated by carbamazepine, oxcarbazepine, phenytoin, 
phenobarbital and high doses of topiramate (> 200 mg/d), 
progestin by carbamazepine, oxcarbazepine, lamotrigine, 
phenytoin and phenobarbital. Other AEDs interacting with 
OC are not available in Poland. Lamotrigine concentration 
is reduced by EE and increased seizure frequency has been 
reported. Interaction of EE with AEDs are well known, how-
ever possible interactions of progestin with AEDs are much 
less studied. It has been proved that enzyme-inducing 
AEDs interact with oral levonorgestrel, oral norethindrone 
and the subdermal etonogestrel implant [3]. According 
to recent data more than half of pregnancies in women 
with epilepsy are unplanned; significant percentage of 
patients do not use highly effective methods of contra-
ception or use hormonal contraceptives combined with 
enzyme-inducing AEDs, which can lead to unintended 
pregnancies [4–6].
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Objectives
The aim of the study was to evaluate hormonal con-
traception use in women with epilepsy and to assess the 
risk of potential interactions between contraceptives and 
antiepileptic drugs.
MATERIAL AND METHODS
Study population
The study included consecutive WWE of reproductive 
age (16–49 years) treated at the university epilepsy clinic 
between 01.08. 2017 and 31.08.2018. Participation in the 
study was offered to patients diagnosed with epilepsy as 
defined by the International League Against Epilepsy (ILAE) 
of 2014 [7]. Patients who did not agreed to participate, 
pregnant and breastfeeding patients, patients with primary 
amenorrhea and patients with concomitant psychogenic 
non-epileptic seizures were excluded from the study. 
The study protocol was approved by the University Ethi-
cal Committee and all subjects gave their written consent 
to participate in the study.
Methods
Demographic and epilepsy data were collected using 
a structured questionnaire and included: age, sex, age at the 
onset of epilepsy, type and frequency of seizures, AEDs treat-
ment. The type of epilepsy was diagnosed on the basis of 
the interview, neurological examination, neuroimaging and 
electroencephalogram. Epilepsy type has been classified 
according to the new ILAE position paper on classification 
of epilepsies [8]. Data on hormonal contraception used by 
patients were obtained prospectively from patients during 
two subsequent visits to the clinic. The potential for interac-
tion between AEDs and hormonal contraceptives has been 
assessed on the basis of Reimers et al. [3]. Enzyme-inducing 
AEDs used by studied women included carbamazepine, 
oxcarbazepine and topiramate > 200 mg daily.
RESULTS
Sample characteristics
Among 405 female patients who were seen in the 
epilepsy clinic within the period of the study, 334 fertile 
women met the inclusion criteria and entered the study. 
The average age of the analyzed patients was 30.2 (± 7.73). 
193 (57.8%) patients were on monotherapy, polytherapy 
was used in 141 (42.2%) of the studied women. The most 
commonly used AEDs included valproate, levetiracetam and 
lamotrigine. At the time of the assessment 127 (36.2%) of the 
patients were in remission. Counseling regarding the effec-
tive methods of contraception and the possible teratogenic 
effects of the medication on the fetus were documented in 
a written form in patients’ health records in all WWE taking 
valproate or/and topiramate and in 89% (297) of the whole 
group. Table 1 presents demographics, the characteristics of 
epilepsy and its treatment in the studied group.
Hormonal contraception
Of the 334 WWE participating in the study, 19 (5.7%) 
patients in an average age of 27.6 (20–43) years reported 
the current use of hormonal contraception (18- combined 
hormonal contraceptive, 1 progestin-only pill). No women 
used hormonal patch, vaginal ring, implanted progestin or 
depomedroxyprogesterone. The precise characteristics of 
AEDs used by these patients as well as hormonal contracep-
tion are presented in Table 2.
Of the patients on OC, the majority (12; 63%) had a po-
tential for drug-drug interactions. Only 7 women (37%) of 
all those on hormonal contraception used preparations that 
did not interact with AEDs. Additionally 7 patients used sex 
hormones for other indications (menstrual regulation or 
hormone replacement therapy): 2 patients — dydrogester-
one, 2 — progesterone, 1 — estradiol, 1 — estradiol / nore-
thisterone, 1 — estradiol / norgestrel. All patients from this 
group were on non-enzyme-inducing AEDs (LEV, VPA, VGB). 
Table 1. Clinical characteristics of the study patients
Variable N = 334
Age [years]
Age at onset of epilepsy
30.2 (16–49)
15.0 (1–43)
Type of epilepsy
•	 focal 
•	 genetic (idiopathic) generalized 
•	 combined focal & generalized or unknown
227 (70.0%)
96 (28.7%)
11 (3.3%)
Number of AEDs used
•	 1
•	 2
•	 3
•	 4
193 (57.8%)
104 (31.2%)
32 (9.6%)
5 (1.4%)
Seizure frequency 
•	 more than 1 per month
•	 less than 1 per month, more than 1 per year
•	 less than 1 per year
121 (36.2%)
86 (25.8%)
127 (38.0%)
The most commonly used AEDs (in mono-or polytherapy)
Valproate
•	 levetiracetam
•	 lamotrigine
•	 carbamazepine
•	 topiramate
135
121
98
56
39
Place of residence
•	 village or town < 20 000
•	 large town 20 000–100 000
•	 city 100 000–1000 000
198 (59.3%)
80 (24%) 
56 (16.7%)
Education
•	 none 
•	 primary school 
•	 vocational/secondary school
•	 university degree
68 (20.3%)
18 (5.4%)
201 (60.2%)
47 (14.1%)
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AEDs with teratogenic potential
Nearly half of the patients (145; 46%) who did not use 
hormonal contraceptives were on AEDs with known terato-
genic potential (128 VPA, 17 TPM). In 68 patients of the initial 
cohort the future pregnancy was extremely unlikely due to 
concurrent severe disabilities (severe mental retardation, 
being in a nursing home, significant paresis). They were 
excluded from the analysis. The remaining group consisted 
of 266 women, of whom 19 (7.1%) used OC. Out of 247 WWE 
not using hormonal contraception, 84 (37%) were on AEDs 
with the highest risk of teratogenicity: VPA or TPM.
DISCUSSION
Our work showed a very low percentage of WWE us-
ing hormonal contraceptives (5.7%). In a study of patients 
with epilepsy in the US, as many as 46.6% used hormonal 
contraception [5]. The results of study by Polish authors, 
focused on general population also showed a significantly 
higher percentage of OC usage in the Polish general popu-
lation (31.2%) [9]. There may be several reasons for such 
a low percentage of OC usage in our cohort. With regard 
to religion, the vast majority of Polish population (88%) is 
Roman catholic and may accept only methods of natural 
family planning [10]. Only 14% of patients had a university 
degree and most of them (60%) lived in villages or small 
towns, these factor my negatively affect knowledge and 
availability of the effective contraceptive methods. Several 
other reasons may play a role in not using contraception 
by WWE: concerns about its efficacy and interactions with 
AEDs, sides effects of hormonal OC, menstrual problems 
and increased seizure frequency [11].
Every woman of childbearing age treated in our epilepsy 
clinic receives counseling on a contraception plan and on 
the teratogenicity of AEDs. Despite this, the proportion of 
patients using hormonal contraceptives is very low. In the 
case of using drugs with high risk of teratogenicity (VPA, 
TMP), the patient is counselled on effective methods of 
contraception during each subsequent visit, and a plan for 
changing the pharmacotherapy of epilepsy is also present-
ed. Unfortunately, most patients, especially those who are 
in remission, do not agree to change therapy. 
Furthermore, 60% of the patients taking oral contracep-
tives were on AEDs which could have significant pharma-
cokinetic interactions with hormonal preparations. These 
were: induction of hepatic metabolism of OC by CBZ or 
OXC, and thus the possibility of reducing the contracep-
tive effectiveness. The second, more frequent mechanism 
of interaction, involved the stimulation of UDP-glucuronyl 
Table 2. Hormonal contraceptives, AEDs and interaction risk in the studied patients
AEDs Estrogen Progestogen Interaction riska 
OXC estradiol nomegestrol 1
CBZ ethinylestradiol norgestimate 1
LTG ethinylestradiol gestodene 2
LEV ethinylestradiol gestodene 3
LEV OXC ethinylestradiol gestodene 1
OXC ethinylestradiol gestodene 1
LEV ethinylestradiol norgestimate 3
VPA ethinylestradiol norgestimate 3
LEV LTG ethinylestradiol drospirenone 2
VPA LTG LEV ethinylestradiol norgestimate 2
VPA LEV ethinylestradiol norgestimate 3
VPA ethinylestradiol norgestimate 3
VPA LTG ethinylestradiol gestodene 2
LTG ethinylestradiol dienogest 2
VPA ethinylestradiol gestodene 3
LTG ethinylestradiol norgestimate 2
LTG ethinylestradiol gestodene 2
LTG VGB ethinylestradiol dienogest 2
LEV desogestrel 3
a1 — reduced efficacy of OC; 2 — decreased concentration of AED; 3 — without clinically significant interactions; abbreviations: CBZ — carbamazepine; LTG — lamotrigine; 
LEV — levetiracetam; OXC — oxcarbazepine; VPA — valproate; VGB — vigabatrin
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transferase by the estrogen component of hormonal con-
traception, thereby reduction of the concentration and ef-
ficacy of lamotrigine. Our results are in line with the study 
of Bhakta et al. [4] and indicate that knowledge gaps exist 
in terms of the potential teratogenic effects of AEDs and 
pharmacokinetic interactions between AEDs and OC.
Out of 247 childbearing age women who could become 
pregnant and did not use hormonal contraception, 84 (37%) 
were on AEDs with the highest risk of teratogenicity: VPA or 
TPM. According to the recently published European Medi-
cine Agency recommendation valproate must not be used 
in women able to have children unless the terms of a special 
pregnancy prevention programs are followed [12].
Appropriate counseling on the forms of hormonal con-
traception, suited for WWE expectations and needs is crucial 
for the selection of an optimal birth control method [11, 13]. 
Polish Society of Epileptology and Polish Gynecological 
Society have developed guidelines regarding management 
and care of WWE of childbearing potential, which underline 
the importance of counseling regarding contraceptive or 
pregnancy planning and the choice of AEDs [14]. 
Combined OC and progestin-only pill efficacy may be re-
duced by enzyme-inducing AEDs. Other hormonal contracep-
tive methods, such as medroxyprogesterone acetate depot in-
jection, or implantable hormonal contraceptive may have some 
interaction with AEDs. Nonhormonal, highly effective methods, 
such as IUDs, may be ideal for women with epilepsy, since the 
contraceptive mechanism of IUDs is unaffected by changes 
in hepatic enzyme activity [14–16]. What’s more, IUD poses 
a significantly lower risk for seizure increase in WWE than hor-
monal contraception [17]. In WWE using a hormonal-IUD, 
a levonorgestrel level seems to be unaffected by concomitant 
AEDs therapy [18]. The role of gynecologist in counseling on 
the forms of hormonal contraception is indispensable for ap-
propriate management of WWE in childbearing age.
Our research has several disadvantages. First of all, it was 
carried out in a reference outpatient epilepsy clinic in which 
we treat patients with drug-resistant epilepsy often requir-
ing polytherapy or using drugs with a higher potential for 
teratogenicity. For this reason, a group of patients may not 
be representative of the general population of women with 
epilepsy. The second disadvantage is the lack of a control 
group. Therefore, it can only be concluded indirectly that 
the frequency of OC usage in patients with epilepsy is lower 
than in the Polish population of women in reproductive 
age. Thirdly, information on the use of other methods of 
contraception, in particular highly effective methods, such 
as the intrauterine device (tubal ligation and vasectomy 
are legally prohibited in Poland), has not been collected. In 
the studies of Bakhta et al. [4] and Herzog et al. [5], IUD was 
used by 6.1% and 17% of WWE respectively.
 CONCLUSIONS
A very small percentage of WWE in reproductive age 
used oral hormonal contraception. The ones using con-
traception frequently applied method that had significant 
drug–drug interaction which reduced the effectiveness of 
OC or AED(s). A large proportion of women who were hav-
ing AEDs with high risk of teratogenicity prescribed were 
not using hormonal contraception. It is advisable to create 
gynecological-neurological teams, caring for WWE in repro-
ductive age, and to take care about continuous education 
of patients regarding effective methods of family planning 
and about improvement of methods of informing patients 
about the teratogenicity of AEDs. Nonhormonal, highly 
effective methods, such as IUDs, may be ideal for women 
with epilepsy.
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